A NEW QUANTITATIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE ANALYSIS OF BOCEPREVIR IN BULK AND MARKETED FORMULATION
Abstract
A simple, precise and accurate RP-HPLC technique was developed and the developed method was validated for the regular analysis of Boceprevir. Chromatographic analysis was performed by selecting X-Terra ODS ( C18) column (4.6 mm i.d. × 250 mm, 5μ), Acetonitrile : Phosphate buffer pH -3 ( 90 : 10% v/v) as mobile phase, 1.0 ml/min as flow rate and 20μl injection volume. The LC chromatographic peak was eluted at 3.6 min at 235 nm as UV detection wavelength. The developed method was validated as per the ICH guidelines and the Validation parameters were specificity, accuracy, linearity, precision, LOD and LOQ. Linear relationship for Boceprevir established in the concentration range of 50 to 150μg/mL. Accuracy in terms of percentage recovery found in the range between 98 to 101%. LOD and LOQ values were found to be 2.3 and 7.123μg/mL respectively. The results of the method established that the new RP-HPLC method is convenient and simple in regular analysis of Boceprevir in bulk and capsule formulation.
Keywords:
Boceprevir, Protease-inhibitor, Hepatitis-C, RP-HPLC, Accuracy, ICH guidelinesDOI
https://doi.org/10.25004/IJPSDR.2018.100314References
2. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res. 2008; 41 (1): 50–9.
3. American Association for the study of Liver Diseases; Infectious Diseases Society of America. HCV Guidance. http://hcvuidelines.org. Accessed June 12, 2017.
4. Bagaglio S, Uberti-Foppa C, Morsica G. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Viruses. 2017; 77(10):1043-1055.
5. Govardhan Reddy P, Kiran Kumar V, Appala Raju, VVSS, Raghu Ram J, Appala Rraju N. Novel Spectrophotometric Method Development for the Estimation of Boceprevir in Bulk and in Pharmaceutical Formulations. Research J. Pharm. and Tech 2017; 10(12): 4313-4316.
6. Ganji S, Satyavati D. Development and Validation of RP – HPLC Method for the Analysis of Boceprevir and Related Impurities in Bulk and Pharmaceutical Dosage Forms. Indo American Journal of Pharmaceutical Research. 2015; 5(6): 2391-2401.l
7. Damle MC, Salunke SR. Development and Validation of Stability Indicating HPLC Method for Determination of Boceprevir. International Research Journal of Pharmacy. 2016; 7(8):47-53.
8. Chandramowli B, Rajkamal BB. A Validated LC-MS/MS Method for the Estimation of Boceprevir and Boceprevir D6 (IS) in Human Plasma Employing Liquid-Liquid Extraction. International Journal of Pharmacy and Pharmaceutical Sciences. 2016; 8(7): 133-137.
9. Harald Farnik H, El-Duweika J, Welsch C, et al. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC–MS/MS. Journal of Chromatography B. 2009; 877(31):4001-4006.
10. International conference on harmonization (ICH), Validation of Analytical Procedures: text and methodology Q2 (R1), Geneva, 2005.
Published
Abstract Display: 427 
PDF Downloads: 0 
